TNF-alpha (TNFα) inhibitors suppresses response to tumor necrosis factor, part of the inflammatory response. TNFα Inhibitors are used to treat a number of inflammatory disorders including rheumatoid arthritis and Crohn's disease.
Currently, the sales for injectable TNFα inhibitors are more than $30 billion. The Rani product could transform this therapy replacing painful, biweekly injections with a daily pill.
Commonly used for the treatment of osteoporosis, PTH increases the concentration of calcium in the blood by acting upon the parathyroid hormone 1 receptor and the parathyroid hormone 2 receptor.
The top injectable product in this category has sales of more than $1.5B. The Rani product could transform this therapy replacing painful, daily injections with daily pills.
Human Growth Hormone (HGH) is a peptide hormone that stimulates growth, cell reproduction and regeneration, and is used in the treatment of growth disorders and growth deficiency.
The global market for injectable HGH is more than $3B, and is projected to $4.3B by 2018. The Rani product could transform this therapy replacing painful weekly or daily injections with daily pills.
Somatostatin, also known as growth hormone-inhibiting hormone (GHIH), regulates insulin and glucagon. The drug is currently used to treat a number of indications including Enteroendocrine tumors (in the stomach, intestine or pancreas), and Acromegaly, a rare disease that causes the body's soft tissues and organs to grow too much, causing pain, fatigue, excessive sweating, among other symptoms. Patients suffering from these conditions currently receive painful, deep intramuscular injections every four weeks.
Sales of injectable Somatostatin exceeded $2B in 2013. The Rani platform could transform this therapy with daily pills.
Human Interferon beta -1a is a cytokine or small protein in the interferon family used for the treatment of multiple sclerosis. Although not a cure, it is believed that interferons may slow the progress of multiple sclerosis if started early and continued for the duration of the disease. Current therapy includes painful weekly intramuscular injections or subcutaneous injections 3x/week.
Sales of injectable Human Interferon b exceeded $7B in 2012 in the US. The Rani platform could transform this therapy with daily pills.
Glucagon-like peptide-1 agonists or GLP-1 mimetics are a class of drugs used in the treatment of Type II diabetes and obesity. Available GLP-1 agonists include exenatide, liraglutide and lixisenatide. Currently, patients must administer a daily or weekly injection.
The combined sales of GLP-1 mimetics is more than $2.5 billion. The Rani platform could transform this therapy with daily pills.
Unique to the Rani platform, combination therapies can also be delivered and are ideally suited for the treatment of Type II diabetes.
The drug market for Type 2 Diabetes exceeds $20B. The Rani platform could deliver this combination therapy with daily pills.
Interleukin-17 (IL-17) is a cytokine target which is gaining attention for its use in treating various inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis, among others. Recent studies of compounds in late stage development have indicated the superior efficacy of IL-17 inhibitors as compared to a TNF-alpha inhibitor.
Millions of patients suffer from conditions that require painful injections as the majority of biologics can only currently be administered via intramuscular or subcutaneous routes. These injections affect quality of life, and as a result, patient compliance can also become an issue.
The Rani product offers an innovative alternative: replacing injections with an oral pill. Suitable for a variety of injectable drugs, the Rani product would radically improve the patient's experience. Instead of a painful injection, patients would have a choice to take a daily pill. It is simple, easy and pain-free. We are currently evaluating a number of biologics for delivery on the Rani platform.
Scores of attempts have been made to deliver biologics orally, and all have failed. We believe Rani's approach will transform the market, and we are on the way to proving that it is nothing short of a breakthrough.